相关实验视频

Updated: Jun 13, 2025

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

DPP-4 抑制剂改善了糖尿病大鼠的认知功能

Ying Hu^1,2,3, Jiancheng Wang^1,2,3, Jiao Wang^1,2,3

¹Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.

Journal of healthcare engineering

|September 16, 2024

概括

萨克萨格利普丁是一种二二二酶-4 (DPP-4) 抑制剂,在糖尿病老鼠中改善了认知功能. 这种DPP-4抑制剂减少了炎症和陶酸化,为糖尿病相关的认知功能障碍提供了潜在的治疗方法.

科学领域:

神经科学是一个神经科学.
内分泌学在内分泌学.
药理学药理学是指药理学的学科.

背景情况:

糖尿病相关的认知功能障碍是一个重大的全球健康问题.
双基化酶-4 (DPP-4) 抑制剂通常用于糖尿病管理.
DPP-4 抑制剂对糖尿病患者认知功能的影响需要进一步研究.

研究的目的:

为了研究DPP-4抑制剂萨克萨格利普丁对糖尿病大鼠模型认知功能的影响.
阐明萨克萨格利普丁作用的潜在机制,包括抗炎和抗陶酸化.

主要方法:

建立糖尿病老鼠模型来诱导认知功能障碍.
使用莫里斯水迷宫任务评估认知功能.
通过西式涂抹和免疫组织化学量化炎症标志物 (互白素-1β,GFAP) 和化.

主要成果:

糖尿病诱导了老鼠的认知功能障碍,莫里斯水迷宫任务的表现证明了这一点.
萨克萨格利普丁治疗改善了糖尿病大鼠的认知缺陷.
萨克萨格利普丁通过降低海马体内白内素-1β和GFAP水平来表现出抗炎作用.
萨克萨格利普丁表现出反的酸化作用.

结论:

这项研究提供了第一个证据,即DPP-4抑制剂,特别是萨克萨格利普丁,可以缓解糖尿病大鼠的认知功能障碍.
萨克萨格利普丁的治疗作用通过抗炎和抗陶酸化机制进行介导.
这些发现表明,萨克萨利普丁是治疗糖尿病相关认知功能障碍的潜在治疗剂.

更多相关视频

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats

Published on: October 23, 2020

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models

Published on: October 20, 2017

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...